DNA anniversary Nov Story Banner

First identified in 1958 by Jean Dausset, human leukocyte antigens (HLAs) give each individual’s immune system the ability to determine self from “non-self”. Cells displaying “non-self” antigens are seen as invaders by the immune system, and thus, tissues bearing these cells are rejected. This is particularly important for transplant biology and underscores the necessity of HLA-matched donors and recipients in organ and bone marrow transplants.

Prior to transplantation, organs and bone marrow are typically matched by analyzing four to six genes (A, B, C, DR, DQ, and DP) that encode the HLAs found on the surface of all cells in the body. Individuals vary widely in HLA subtypes. Tissue typing by HLA analysis reduces the possibility of transplant rejection or other diseases such as graft-versus-host disease (GVHD).

The future of HLA typing and characterization lies in new diagnostic tools. The 3500 Dx Genetic Analyzer CS2 is the latest addition to our family of Applied Biosystems® genetic analyzers based on capillary electrophoresis. The 3500 Dx Genetic Analyzer CS2 is an IVD-labeled instrument, making it the first Sanger sequencing platform cleared for HLA sequence analysis of DNA in the US and Canada.

The following streamlined workflow for HLA typing uses Applied Biosystems® PCR and sequencing technologies, and Invitrogen™ sample prep and HLA kits and software.

Figure 1. The Life Technologies SBT workflow produces high-resolution sequence data your lab depends on. Requires POP-6™ polymer for improved short-fragment resolution, 600 bp read length, and a run time of about an hour. 

For research use only. Not for use in diagnostic procedures.